MNG624
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- OXIDATIVE_PHOSPHORYLATION+0.458
- PROTEIN_SECRETION+0.436
- MTORC1_SIGNALING+0.370
- ADIPOGENESIS+0.344
- ANGIOGENESIS+0.334
- GLYCOLYSIS+0.316
- PI3K_AKT_MTOR_SIGNALING+0.307
- UNFOLDED_PROTEIN_RESPONSE+0.237
- HYPOXIA+0.225
- ANDROGEN_RESPONSE+0.201
Top 10 suppressed
- INTERFERON_GAMMA_RESPONSE-0.374
- INTERFERON_ALPHA_RESPONSE-0.345
- E2F_TARGETS-0.339
- G2M_CHECKPOINT-0.333
- ALLOGRAFT_REJECTION-0.294
- IL6_JAK_STAT3_SIGNALING-0.264
- SPERMATOGENESIS-0.187
- INFLAMMATORY_RESPONSE-0.185
- KRAS_SIGNALING_DN-0.132
- KRAS_SIGNALING_UP-0.122
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
7 twins match this tumor's tissue · 3 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | BS_TBWYAFSM | EPN | EPN Tumor | 0.774 |
| 2 | TCGA-BH-A1EN-01A-11R-A13Q-07 | — | C | 0.771 |
| 3 | C3L-01632 | — | cohortA4 | 0.764 |
| 4 | SJEPD030784_D1.RNA-Seq | EPN | Myxopapillary EPN | 0.761 |
| 5 | SRR8518245 | — | F | 0.755 |
| 6 | R319 | — | — | 0.752 |
| 7 | BS_TBWYAFSM | Spinal Cord Ependymoma | — | 0.752 |
| 8 | SRR10899980 | — | — | 0.750 |
| 9 | TCGA-E2-A1LB-01A-11R-A144-07 | — | F | 0.747 |
| 10 | SRR12696732 | — | — | 0.744 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 26 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| OXIDATIVE_PHOSPHORYLATION | 0.458 | Remibrutinib | — uncovered |
| PROTEIN_SECRETION | 0.436 | Remibrutinib | — uncovered |
| MTORC1_SIGNALING | 0.370 | Inavolisib | — uncovered |
| ADIPOGENESIS | 0.344 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.334 | Remibrutinib | — uncovered |
| GLYCOLYSIS | 0.316 | Inavolisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.307 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.237 | Idelalisib | — uncovered |
| HYPOXIA | 0.225 | Idelalisib | — uncovered |
| ANDROGEN_RESPONSE | 0.201 | Inavolisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.160 | Remibrutinib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.153 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.129 | Idelalisib | — uncovered |
| HEME_METABOLISM | 0.122 | Temsirolimus | — uncovered |
| P53_PATHWAY | 0.116 | Idelalisib | — uncovered |
| BILE_ACID_METABOLISM | 0.099 | Inavolisib | — uncovered |
| UV_RESPONSE_DN | 0.096 | Inavolisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.092 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.087 | Inavolisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.071 | Inavolisib | — uncovered |